{"analyses":[{"ciLowerLimit":"0.15","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.26","estimateComment":"Stratified by Binet stage at Baseline.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.0001","paramType":"Hazard Ratio (HR)","paramValue":"0.19","statisticalMethod":"Log Rank, Stratified"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"23.9","upperLimit":"32.9","value":"28.7"},{"groupId":"OG001","lowerLimit":"8.0","upperLimit":"11.1","value":"10.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"238"},{"groupId":"OG001","value":"118"}],"units":"Participants"}],"description":"Event-free survival (EFS) was defined as the time between date of randomization and the date of disease progression/relapse, death, or start of a new anti-leukemic therapy. Progressive disease as per IWCLL criteria required at least one of the following: ≥50% increase in the absolute number of lymphocytes, appearance of new palpable lymph nodes (\\>15 mm in longest diameter) or any new extra nodal lesion, ≥50% increase in the longest diameter of any previous site of clinically significant lymphadenopathy, ≥50% increase in the enlargement of the liver and/or spleen, Transformation to a more aggressive histology or After treatment, the progression of any cytopenia (a decrease of hemoglobin levels \\>20 g/L or \\<10 g/dL or a decrease of platelet counts \\>50% or \\<100 x 10\\^9/L or by a decrease of neutrophil counts \\>50% or \\<1.0 x 10\\^9/L).","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received 1000 mg obinutuzumab intravenous (IV) infusion, on Days 1 \\[first infusion split 100 mg on Day 1 and 900 mg on Day 2 as per protocol amendment\\], 8 and 15 in Cycle 1 and Day 1 in Cycles 2-6 (28-day cycles) plus chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle (6 Cycles).","id":"OG000","title":"Obinutuzumab + Chlorambucil (GClb)"},{"description":"Participants received chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle (6 Cycles). Participants with Progressive Disease or within 6 months of follow-up were allowed to cross over to receive obinutuzumab + chlorambucil.","id":"OG001","title":"Chlorambucil (Clb)"}],"paramType":"MEDIAN","populationDescription":"Intent-to-treat population included all randomized participants. Patients without EFS events were censored.","reportingStatus":"POSTED","timeFrame":"Randomization to clinical cutoff date of 10 Oct 2017 (median observation 62.5 months from randomization)","title":"Event Free Survival","type":"SECONDARY","unitOfMeasure":"Months"}